N. Leone, N. Voirin, L. Roche, F. Binder-foucard, A. Woronoff et al., , 2015.

D. Sur, Abate-Shen C, Shen MM. Molecular genetics of prostate cancer, Genes Dev. 10 janv, vol.14, pp.2410-2444, 2000.

M. S. Litwin and H. Tan, The Diagnosis and Treatment of Prostate Cancer: A Review, JAMA. 27 juin, vol.317, issue.24, pp.2532-2574, 2017.

I. F. Tannock, R. De-wit, W. R. Berry, J. Horti, A. Pluzanska et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, vol.351, issue.15, pp.1502-1512, 2004.

D. P. Petrylak, C. M. Tangen, M. H. Hussain, L. Jr, P. N. Jones et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, vol.351, issue.15, pp.1513-1520, 2004.

E. J. Small, P. F. Schellhammer, C. S. Higano, C. H. Redfern, J. J. Nemunaitis et al.,

, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.24, pp.3089-94, 2006.

C. Parker, S. Nilsson, D. Heinrich, S. I. Helle, J. M. O'sullivan et al., Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med. 18 juill, vol.369, issue.3, pp.213-236, 2013.

J. S. De-bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet, vol.376, pp.1147-54, 2010.

C. J. Ryan, M. R. Smith, J. S. De-bono, A. Molina, C. J. Logothetis et al., Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, N Engl J Med. 10 janv, vol.368, issue.2, pp.138-186, 2013.

K. Fizazi, H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi et al., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, vol.13, issue.10, pp.983-92, 2012.

T. M. Beer, A. J. Armstrong, D. E. Rathkopf, Y. Loriot, C. N. Sternberg et al.,

, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, N Engl J Med. 31 juill, vol.371, issue.5, pp.424-457, 2014.

H. I. Scher, K. Fizazi, F. Saad, M. Taplin, C. N. Sternberg et al., Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

M. T. Schweizer, X. C. Zhou, H. Wang, S. Bassi, M. A. Carducci et al., The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer, Eur Urol, vol.66, issue.4, pp.646-52, 2014.

J. Mezynski, C. Pezaro, D. Bianchini, A. Zivi, S. Sandhu et al., Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for crossresistance?, Ann Oncol Off J Eur Soc Med Oncol, vol.23, issue.11, pp.2943-2950, 2012.

B. L. Maughan, X. C. Xhou, D. L. Suzman, R. Nadal, S. Bassi et al., Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. The Prostate, vol.75, pp.1814-1834, 2015.

R. J. Van-soest, E. S. De-morrée, C. F. Kweldam, C. De-ridder, E. Wiemer et al., Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer, Eur Urol. juin, vol.67, issue.6, pp.981-986, 2015.

A. Nakouzi, N. , L. Moulec, S. Albigès, L. Wang et al.,

, Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies, Eur Urol. août, vol.68, issue.2, pp.228-263, 2015.

M. Zhu, C. M. Horbinski, M. Garzotto, D. Z. Qian, T. M. Beer et al., Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer, Cancer Res, vol.15, issue.20, pp.7992-8002, 2010.

P. Grosclaude, A. Belot, D. Marliac, L. Remontet, L. Leone et al., Le cancer de la prostate, évolution de l'incidence et de la mortalité en France entre, Prog En Urol. 1 juill, vol.25, issue.9, pp.536-578, 1980.

F. H. Schröder, J. Hugosson, M. J. Roobol, T. Tammela, M. Zappa et al., Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, The Lancet. 6 déc, vol.384, issue.9959, pp.2027-2062, 2014.

J. H. Hayes and M. J. Barry, Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence, JAMA. 19 mars, vol.311, issue.11, pp.1143-1152, 2014.

N. Mottet, J. Bellmunt, M. Bolla, E. Briers, M. G. Cumberbatch et al., EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, Eur Urol, vol.71, issue.4, pp.618-647, 2017.

S. Sutcliffe and G. A. Colditz, Prostate cancer: is it time to expand the research focus to early-life exposures?, Nat Rev Cancer. mars, vol.13, issue.3, pp.208-518, 2013.

K. H. Barry, J. I. Martinsen, M. Alavanja, G. Andreotti, A. Blair et al., Risk of earlyonset prostate cancer associated with occupation in the Nordic countries, Eur J Cancer. 1 déc, vol.87, pp.92-100, 2017.

C. A. Salinas, A. Tsodikov, M. Ishak-howard, and K. A. Cooney, Prostate cancer in young men: an important clinical entity, Nat Rev Urol. juin, vol.11, issue.6, pp.317-340, 2014.

G. L. Andriole, E. D. Crawford, R. L. Grubb, S. S. Buys, D. Chia et al., Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up, JNCI J Natl Cancer Inst, vol.104, issue.2, pp.125-157, 2012.

J. H. Jung, J. Kim, R. Macdonald, B. Reddy, M. H. Kim et al., Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia, Cochrane Database Syst Rev, vol.22, p.12615, 2017.

G. R. Cunha, Growth factors as mediators of androgen action during male urogenital development, Prostate Suppl, vol.6, pp.22-27, 1996.

G. R. Cunha, A. A. Donjacour, P. S. Cooke, M. S. Bigsby, R. M. Higgins et al., The endocrinology and developmental biology of the prostate, Endocr Rev. août, vol.8, issue.3, pp.338-62, 1987.

A. Y. Liu, L. D. True, L. Latray, W. J. Ellis, R. L. Vessella et al., Analysis and sorting of prostate cancer cell types by flow cytometry. The Prostate. 1 août, vol.40, pp.192-201, 1999.

A. P. Verhagen, F. C. Ramaekers, T. W. Aalders, H. E. Schaafsma, F. M. Debruyne et al.,

, Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer, Cancer Res, vol.52, issue.22, pp.6182-6189, 1992.

C. Zenzmaier, G. Untergasser, and P. Berger, Aging of the prostate epithelial stem/progenitor cell, Exp Gerontol, vol.43, issue.11, pp.981-986, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00499059

G. Lapouge, Mécanismes d'action d'une nouvelle classe de mutations du récepteur des androgènes dans les cancers de la prostate, 2007.

E. S. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa et al., AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

F. Qu, W. Xie, M. Nakabayashi, H. Zhang, S. H. Jeong et al., Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer, Disponible sur, vol.23, pp.726-760, 2017.

G. Zhang, X. Liu, J. Li, E. Ledet, X. Alvarez et al., Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents, Oncotarget, vol.6, issue.27, p.23358, 2015.

D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer, Cell. 7 janv, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell. 4 mars, vol.144, pp.646-74, 2011.

C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, vol.44, issue.6, pp.685-694, 2012.

B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao et al., Integrative genomic profiling of human prostate cancer, Cancer Cell. 13 juill, vol.18, issue.1, pp.11-22, 2010.

H. Hieronymus, N. Schultz, A. Gopalan, B. S. Carver, M. T. Chang et al., Copy number alteration burden predicts prostate cancer relapse, Proc Natl Acad Sci U S A. 29 juill, vol.111, issue.30, pp.11139-11183, 2014.

S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, vol.310, pp.644-652, 2005.

A. Abeshouse, J. Ahn, R. Akbani, A. A. Amin, S. Andry et al., The Molecular Taxonomy of Primary Prostate Cancer. Cell, vol.163, pp.1011-1036, 2015.

A. Gopalan, M. A. Leversha, J. M. Satagopan, Q. Zhou, H. A. Al-ahmadie et al.,

, TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy, Cancer Res. 15 févr, vol.69, issue.4, pp.1400-1406, 2009.

A. Pettersson, R. E. Graff, S. R. Bauer, M. Pitt, R. T. Lis et al., Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. sept, vol.2, issue.9, pp.1497-509, 2012.

S. D. Kaffenberger and C. E. Barbieri, Molecular subtyping of prostate cancer, Curr Opin Urol. mai, vol.26, issue.3, pp.213-221, 2016.

D. Robinson, E. M. Van-allen, Y. Wu, N. Schultz, R. J. Lonigro et al.,

, Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 16 juill, vol.162, issue.2, p.454, 2015.

A. Modena, R. Iacovelli, A. Scarpa, M. Brunelli, C. Ciccarese et al., Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer, Target Oncol, vol.11, issue.5, pp.569-77, 2016.

L. Salomon, C. Bastide, P. Beuzeboc, L. Cormier, G. Fromont et al., Recommandations en onco-urologie 2013 du CCAFU : Cancer de la prostate, Prog En Urol. nov, vol.23, pp.69-101, 2013.

J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley et al., Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of, vol.40, pp.244-52, 2014.

C. Huggins and C. V. Hodges, Studies on prostatic cancer. I. The effet of castration of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate, Cancer Res, vol.1, p.293, 1941.

G. Tolis, M. Koutsilieris, R. Herrera, A. Stellos, A. Martinez et al., Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH, Med Oncol Tumor Pharmacother, vol.1, issue.2, pp.129-165, 1984.

G. J. Kolvenbag, G. R. Blackledge, K. Gotting-smith, and . Bicalutamide, Casodex) in the treatment of prostate cancer: history of clinical development. The Prostate, janv, vol.1, issue.1, pp.61-72, 1998.

M. Wirth, C. Tyrrell, K. Delaere, M. Sánchez-chapado, R. J. Wallace et al.,

. Bicalutamide, Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme, Prostate Cancer Prostatic Dis, vol.8, issue.2, pp.194-200, 2005.

P. Iversen, Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators, Eur Urol, vol.26, issue.1, pp.5-9, 1994.

L. Klotz, L. Boccon-gibod, N. D. Shore, C. Andreou, B. Persson et al., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU Int. déc, vol.102, issue.11, pp.1531-1539, 2008.

P. Cornford, J. Bellmunt, M. Bolla, E. Briers, D. Santis et al., EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer, Eur Urol, vol.71, issue.4, pp.630-672, 2017.

U. E. Studer, P. Whelan, W. Albrecht, J. Casselman, T. De-reijke et al., Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891, J Clin Oncol Off J Am Soc Clin Oncol. 20 avr, vol.24, issue.12, pp.1868-76, 2006.

U. E. Studer, L. Collette, P. Whelan, W. Albrecht, J. Casselman et al., Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891), Eur Urol. mai, vol.53, issue.5, pp.941-950, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00485606

C. J. Sweeney, Y. Chen, M. Carducci, G. Liu, D. F. Jarrard et al.,

, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med. 20 août, vol.373, issue.8, pp.737-783, 2015.

N. D. James, M. R. Sydes, N. W. Clarke, M. D. Mason, D. P. Dearnaley et al., Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. 19 mars, vol.387, pp.1163-77, 2016.

K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodriguez-antolin et al., Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med, vol.27, issue.4, pp.352-60, 2017.

N. D. James, J. S. De-bono, M. R. Spears, N. W. Clarke, M. D. Mason et al., Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy, N Engl J Med, vol.27, issue.4, pp.338-51, 2017.

G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou et al., Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol. févr, vol.14, issue.2, pp.149-58, 2013.

C. E. Kyriakopoulos, Y. Chen, M. A. Carducci, G. Liu, D. F. Jarrard et al., Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.36, issue.11, pp.1080-1087, 2018.

M. Tucci, V. Bertaglia, F. Vignani, C. Buttigliero, C. Fiori et al., Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis, Eur Urol. 1 avr, vol.69, issue.4, pp.563-73, 2016.

M. R. Sydes, M. R. Spears, M. D. Mason, N. W. Clarke, D. P. Dearnaley et al., Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol, Ann Oncol Off J Eur Soc Med Oncol. 1 mai, vol.29, issue.5, pp.1235-1283, 2018.

H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg et al., Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol. 1 mars, vol.26, issue.7, pp.1148-59, 2008.

G. J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, issue.11, pp.3461-3468, 1999.

M. Nishino, J. P. Jagannathan, and N. H. Ramaiya, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know, AJR Am J Roentgenol. août, vol.195, issue.2, pp.281-290, 2010.

L. Magadoux, N. Isambert, S. Plenchette, J. Jeannin, and V. Laurens, Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (Review), Int J Oncol, vol.24, issue.2014

D. Sur,

B. Mellado, N. Jimenez, M. Marin-aguilera, and O. Reig, Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients, Clin Genitourin Cancer. août, vol.14, issue.4, pp.265-70, 2016.

E. S. Antonarakis, S. T. Tagawa, G. Galletti, D. Worroll, K. Ballman et al.,

N. Randomized, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.28, pp.3181-3189, 2017.

D. P. Petrylak, R. Macarthur, J. O'connor, G. Shelton, A. Weitzman et al., Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer, Semin Oncol, vol.26, issue.5, pp.28-33, 1999.

W. L. Dahut, J. L. Gulley, P. M. Arlen, Y. Liu, K. M. Fedenko et al., Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.22, issue.13, pp.2532-2541, 2004.

N. M. Hahn, S. Marsh, W. Fisher, R. Langdon, R. Zon et al., Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis, Clin Cancer Res Off J Am Assoc Cancer Res, vol.12, pp.6094-6103, 2006.

S. Oudard, E. Banu, P. Beuzeboc, E. Voog, L. M. Dourthe et al., Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer, J Clin Oncol. 20 mai, vol.23, issue.15, pp.3343-51, 2005.

D. R. Berthold, G. R. Pond, F. Soban, R. De-wit, M. Eisenberger et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol Off J Am Soc Clin Oncol. 10 janv, vol.26, issue.2, pp.242-247, 2008.

R. Huo, L. Wang, P. Liu, Y. Zhao, C. Zhang et al., Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death, Mol Med Rep, vol.14, issue.4, pp.3013-3033, 2016.

C. Villanueva, F. Bazan, S. Kim, M. Demarchi, L. Chaigneau et al., Cabazitaxel: a novel microtubule inhibitor, Drugs. 9 juill, vol.71, issue.10, pp.1251-1259, 2011.

M. D. Galsky, A. Dritselis, P. Kirkpatrick, W. K. Oh, and . Cabazitaxel, Nat Rev Drug Discov, 2010.

E. Morrée, R. Van-soest, A. Aghai, C. De-ridder, P. De-bruijn et al.,

I. Helmantel, Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. The Prostate, vol.76, pp.927-963, 2016.

G. Smiyun, O. Azarenko, H. Miller, A. Rifkind, N. E. Lapointe et al., ?III-tubulin enhances efficacy of cabazitaxel as compared with docetaxel, Cancer Chemother Pharmacol. juill, vol.80, issue.1, pp.151-64, 2017.

G. E. Duran, Y. C. Wang, E. B. Francisco, J. C. Rose, F. J. Martinez et al., Mechanisms of resistance to cabazitaxel, Mol Cancer Ther. janv, vol.14, issue.1, pp.193-201, 2015.

J. S. De-bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet Lond Engl, vol.376, issue.9747, pp.1147-54, 2010.

M. Eisenberger, A. Hardy-bessard, C. S. Kim, L. Géczi, D. Ford et al., Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.28, pp.3198-206, 2017.

M. A. Climent, B. Perez-valderrama, B. Mellado, F. Parra, E. M. et al., Weekly cabazitaxel plus prednisone is effective and less toxic for « unfit » metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial, Eur J Cancer Oxf Engl, vol.87, pp.30-37, 1990.

A. Meisel, S. Von-felten, D. R. Vogt, H. Liewen, R. De-wit et al., Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castrationresistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial, Eur J Cancer. mars, vol.56, pp.93-100, 2016.

A. Angelergues, D. Maillet, A. Flechon, M. Ozguroglu, F. Mercier et al., Prostatespecific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer, Eur J Cancer Oxf Engl, vol.50, issue.9, pp.1602-1611, 1990.

C. Buonerba, G. R. Pond, G. Sonpavde, P. Federico, P. Rescigno et al., Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer, Future Oncol Lond Engl. juin, vol.9, issue.6, pp.889-97, 2013.

M. Weiss, H. Ahrend, H. Grossebrummel, P. Ziegler, L. Brandenburg et al.,

, Cytochrome P450 17A1 Inhibitor Abiraterone Acetate Counteracts the Heat Shock Protein 27's Cell Survival Properties in Prostate Cancer Cells, Urol Int, vol.97, issue.1, pp.112-119, 2016.

Z. Li, A. Bishop, M. Alyamani, J. A. Garcia, R. Dreicer et al., Conversion of abiraterone to D4A drives antitumor activity in prostate cancer, Nature. 16 juill, vol.523, issue.7560, pp.347-51, 2015.

Z. Li, M. Alyamani, J. Li, K. Rogacki, M. Abazeed et al., Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy, Nature. 26 mai, vol.533, issue.7604, pp.547-51, 2016.

J. S. De-bono, C. J. Logothetis, A. Molina, K. Fizazi, S. North et al., Abiraterone and Increased Survival in Metastatic Prostate Cancer, N Engl J Med. 26 mai, vol.364, issue.21, pp.1995-2005, 2011.

C. J. Ryan, M. R. Smith, K. Fizazi, F. Saad, P. Mulders et al., Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol. févr, vol.16, issue.2, pp.152-60, 2015.

R. C. Cabot, N. L. Harris, E. S. Rosenberg, J. Shepard, A. M. Cort et al., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

T. M. Beer, A. J. Armstrong, D. Rathkopf, Y. Loriot, C. N. Sternberg et al.,

, Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study, Eur Urol. févr, vol.71, issue.2, pp.151-155, 2017.

G. Comito, C. P. Segura, M. L. Taddei, M. Lanciotti, S. Serni et al., Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts, Oncotarget

K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet. 5 mars, vol.377, pp.813-835, 2011.

J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop et al., DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med, vol.373, issue.18, pp.1697-708, 2015.

O. Sartor and J. S. De-bono, Metastatic Prostate Cancer. Longo DL, éditeur, N Engl J Med. 15 févr, vol.378, issue.7, pp.645-57, 2018.

M. Marín-aguilera, J. Codony-servat, Ò. Reig, J. J. Lozano, P. L. Fernández et al., Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer, Mol Cancer Ther. 1 mai, vol.13, issue.5, pp.1270-84, 2014.

M. Shiota, E. Kashiwagi, A. Yokomizo, A. Takeuchi, T. Dejima et al., Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor, The Prostate. sept, vol.73, issue.12, pp.1336-1380, 2013.

M. Puhr, J. Hoefer, G. Schäfer, H. Erb, S. J. Oh et al., Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205, Am J Pathol. déc, vol.181, issue.6, pp.2188-201, 2012.

K. Nakamura, T. M. Tilli, J. L. Wanderley, A. Palumbo, R. M. Mattos et al., Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells, Tumour Biol J Int Soc Oncodevelopmental Biol Med. févr, vol.37, issue.2, pp.2655-63, 2016.

M. Mimeault, S. L. Johansson, and S. K. Batra, Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1, Br J Cancer. 19 mars, vol.108, issue.5, pp.1079-91, 2013.

Y. Guo, Y. Zang, L. Lv, F. Cai, T. Qian et al., IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-?B pathway in prostate cancer, Mol Med Rep. déc, vol.16, issue.6, pp.9035-9077, 2017.

K. Fizazi, D. Bono, J. S. Flechon, A. Heidenreich, A. Voog et al., Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer, Eur J Cancer Oxf Engl, vol.48, issue.1, pp.85-93, 1990.

K. Wu, D. Xie, Y. Zou, T. Zhang, R. Pong et al., The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.19, issue.17, p.4740, 2013.

K. N. Chi, C. S. Higano, B. Blumenstein, J. Ferrero, J. Reeves et al., Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial, Lancet Oncol. avr, vol.18, issue.4, pp.473-85, 2017.

T. M. Beer, S. J. Hotte, F. Saad, B. Alekseev, V. Matveev et al., OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial, Lancet Oncol, vol.18, issue.11, pp.1532-1574, 2017.

K. N. Chi, E. Y. Yu, C. Jacobs, J. Bazov, C. Kollmannsberger et al., A phase I doseescalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.6, pp.1116-1138, 2016.

E. S. De-morrée, R. Böttcher, R. J. Van-soest, A. Aghai, C. M. De-ridder et al., Loss of SLCO1B3 drives taxane resistance in prostate cancer, Br J Cancer. 6 sept, vol.115, issue.6, pp.674-81, 2016.

D. E. Oprea-lager, I. V. Bijnsdorp, R. J. Moorselaar, .. V. Eertwegh, A. Hoekstra et al., ABCC4 Decreases Docetaxel and Not Cabazitaxel Efficacy in Prostate Cancer Cells In Vitro, Anticancer Res. 2 janv, vol.33, issue.2, pp.387-91, 2013.

P. Kharaziha, D. Chioureas, D. Rutishauser, G. Baltatzis, L. Lennartsson et al., Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel, Oncotarget, vol.6, issue.25, p.21740, 2015.

T. Kato, K. Mizutani, K. Kameyama, K. Kawakami, Y. Fujita et al., Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer, Urol Oncol Semin Orig Investig. sept, vol.33, issue.9, pp.385-400, 2015.

C. Corcoran, S. Rani, K. O'brien, O. Neill, A. Prencipe et al., Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via, Exosomes. Kyprianou N, éditeur. PLoS ONE. 10 déc, vol.7, issue.12, p.50999, 2012.

Z. Lopez-bujanda and C. G. Drake, Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies, J Leukoc Biol. août, vol.102, issue.2, pp.393-406, 2017.

M. Idorn, T. Køllgaard, P. Kongsted, L. Sengeløv, P. Straten et al., Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer, Cancer Immunol Immunother, vol.63, issue.11, pp.1177-87, 2014.

N. Chi, Z. Tan, K. Ma, L. Bao, and Z. Yun, Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer, Int J Clin Exp Med, vol.7, issue.10, pp.3181-92, 2014.

C. Wu, C. Hsieh, C. Lin, W. Chen, J. Hong et al., Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells, J Mol Med Berl Ger, vol.90, issue.11, pp.1343-55, 2012.

P. Kongsted, T. H. Borch, E. Ellebaek, T. Z. Iversen, R. Andersen et al., Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study, Cytotherapy. 1 avr, vol.19, issue.4, pp.500-513, 2017.

A. Modena, C. Ciccarese, E. Fantinel, D. Bimbatti, G. Tortora et al., Metastatic castrationresistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide, Expert Rev Anticancer Ther, vol.15, issue.9, pp.1037-1085, 2015.

A. A. Shafi, A. E. Yen, and N. L. Weigel, Androgen receptors in hormone-dependent and castrationresistant prostate cancer, Pharmacol Ther. déc, vol.140, issue.3, pp.223-261, 2013.

M. Korpal, J. M. Korn, X. Gao, D. P. Rakiec, D. A. Ruddy et al., An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide), Cancer Discov. 1 sept, vol.3, issue.9, pp.1030-1073, 2013.

Y. Li, S. C. Chan, L. J. Brand, T. H. Hwang, K. Silverstein et al., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines, Cancer Res. 15 janv, vol.73, issue.2, pp.483-492, 2013.

M. Del-re, E. Biasco, S. Crucitta, L. Derosa, E. Rofi et al., The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients, Eur Urol. avr, vol.71, issue.4, pp.680-687, 2017.

E. Efstathiou, M. Titus, S. Wen, A. Hoang, M. Karlou et al., Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer, Eur Urol. janv, vol.67, issue.1, pp.53-60, 2015.

I. A. Asangani, K. Wilder-romans, V. L. Dommeti, P. M. Krishnamurthy, I. J. Apel et al., BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer, Mol Cancer Res MCR. avr, vol.14, issue.4, pp.324-355, 2016.

N. Nadiminty, R. Tummala, C. Liu, W. Lou, C. P. Evans et al., NF-kappaB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer, Mol Cancer Ther. août, vol.14, issue.8, pp.1884-95, 2015.

B. Cao, Y. Qi, G. Zhang, D. Xu, Y. Zhan et al., Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy, Oncotarget. 30 mars, vol.5, issue.6, pp.1646-56, 2014.

R. Ferraldeschi, N. Sharifi, R. J. Auchus, and G. Attard, Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer, Clin Cancer Res. 1 juill, vol.19, issue.13, pp.3353-3362, 2013.

M. Kato, C. A. Banuelos, Y. Imamura, J. K. Leung, D. P. Caley et al., Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juin, vol.22, issue.11, pp.2744-54, 2016.

P. Toren, S. Kim, F. Johnson, and A. Zoubeidi, Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer, Culig Z, éditeur. PLOS ONE. 5 avr, vol.11, issue.4, p.152861, 2016.

M. Shiota, J. L. Bishop, A. Takeuchi, K. M. Nip, T. Cordonnier et al., Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer, Oncotarget. 20 avr, vol.6, issue.11, pp.9086-98, 2015.

J. L. Bishop, A. Sio, A. A. Roberts, M. E. Azad, A. A. Chi et al., PD-L1 is highly expressed in Enzalutamide resistant prostate cancer, Oncotarget. 1 janv, vol.6, issue.1, pp.234-276, 2015.

E. S. Antonarakis, C. Lu, B. Luber, H. Wang, Y. Chen et al., Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer, JAMA Oncol. 1 août, vol.1, issue.5, p.582, 2015.

M. M. Bernardo, A. Kaplun, S. H. Dzinic, X. Li, J. Irish et al., Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity, Cancer Res. 15 sept, vol.75, issue.18, pp.3970-3979, 2015.

R. J. Van-soest, M. E. Van-royen, E. S. De-morrée, J. M. Moll, W. Teubel et al., Crossresistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, Eur J Cancer Oxf Engl, vol.49, issue.18, pp.3821-3851, 1990.

D. Bianchini, D. Lorente, A. Rodriguez-vida, A. Omlin, C. Pezaro et al., Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone, Eur J Cancer Oxf Engl, vol.50, issue.1, pp.78-84, 1990.

J. S. De-bono, S. Chowdhury, S. Feyerabend, T. Elliott, E. Grande et al., Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ?24 weeks in Europe, Eur Urol. 22 août, 2017.

Y. Loriot, D. Bianchini, I. E. Sandhu, S. Patrikidou, A. Pezaro et al., Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol Off J Eur Soc Med Oncol. juill, vol.24, issue.7, pp.1807-1819, 2013.

A. J. Schrader, M. Boegemann, C. Ohlmann, T. J. Schnoeller, L. Krabbe et al., Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone, Eur Urol. janv, vol.65, issue.1, pp.30-36, 2014.

S. Badrising, V. Van-der-noort, I. M. Van-oort, H. P. Van-den-berg, M. Los et al., Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castrationresistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer. 1 avr, vol.120, issue.7, pp.968-75, 2014.

S. C. Schmid, A. Geith, A. Böker, R. Tauber, A. K. Seitz et al., Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer, Adv Ther. févr, vol.31, issue.2, pp.234-275, 2014.

A. A. Azad, B. J. Eigl, R. N. Murray, C. Kollmannsberger, and K. N. Chi, Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients, Eur Urol. janv, vol.67, issue.1, pp.23-32, 2015.

D. L. Suzman, B. Luber, M. T. Schweizer, R. Nadal, and E. S. Antonarakis, Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. The Prostate. sept, vol.74, pp.1278-85, 2014.

K. Brasso, F. B. Thomsen, A. J. Schrader, S. C. Schmid, D. Lorente et al., Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis, Eur Urol. août, vol.68, issue.2, pp.317-341, 2015.

H. H. Cheng, R. Gulati, A. Azad, R. Nadal, P. Twardowski et al., Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel, Prostate Cancer Prostatic Dis. juin, vol.18, issue.2, pp.122-129, 2015.

T. Zhang, M. S. Dhawan, P. Healy, D. J. George, M. R. Harrison et al., Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer, Clin Genitourin Cancer. août, vol.13, issue.4, pp.392-401, 2015.

K. L. Noonan, S. North, R. L. Bitting, A. J. Armstrong, S. L. Ellard et al., Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide, Ann Oncol Off J Eur Soc Med Oncol. juill, vol.24, issue.7, pp.1802-1809, 2013.

Y. Yamada, N. Matsubara, K. Tabata, T. Satoh, N. Kamiya et al., Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castrationresistant prostate cancer: a multi-center retrospective analysis, BMC Res Notes, vol.9, issue.1, p.471, 2016.

B. L. Maughan, B. Luber, R. Nadal, and E. S. Antonarakis, Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study: Comparing Sequencing of Abiraterone and Enzalutamide. The Prostate, 2016.

D. Sur,

N. Terada, B. L. Maughan, S. Akamatsu, T. Kobayashi, T. Yamasaki et al., Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castrationresistant prostate cancer: The Kyoto-Baltimore collaboration, Int J Urol Off J Jpn Urol Assoc. juin, vol.24, issue.6, pp.441-449, 2017.

K. Mori, T. Kimura, H. Onuma, S. Kimura, T. Yamamoto et al., Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. The Prostate, vol.77, pp.1144-50, 2017.

F. Maines, O. Caffo, A. Veccia, C. Trentin, G. Tortora et al., Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer, Crit Rev Oncol Hematol. déc, vol.96, issue.3, pp.498-506, 2015.

A. Angelergues, E. Efstathiou, R. Gyftaki, P. J. Wysocki, N. Lainez et al., Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents, Clin Genitourin Cancer. 23 févr, 2018.

S. Oudard, K. Fizazi, L. Sengeløv, G. Daugaard, F. Saad et al., Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.28, pp.3189-97, 2017.

C. Thibault, J. Eymard, A. Birtle, M. Krainer, G. Baciarello et al., Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer, Eur J Cancer Oxf Engl, vol.97, pp.41-49, 1990.

N. Delanoy, Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database, Eur Urol Oncol, 2018.

J. S. De-bono, M. R. Smith, F. Saad, D. E. Rathkopf, P. Mulders et al., Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302, Eur Urol. 8 juill, 2016.

J. M. Fitzpatrick, J. Bellmunt, K. Fizazi, A. Heidenreich, C. N. Sternberg et al., Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel, Eur J Cancer Oxf Engl, vol.50, issue.9, pp.1617-1644, 1990.

F. Maines, O. Caffo, D. Giorgi, U. Fratino, L. Lo-re et al., Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme, Clin Genitourin Cancer. févr, vol.14, issue.1, pp.48-55, 2016.

T. M. Beer, A. J. Armstrong, D. E. Rathkopf, Y. Loriot, C. N. Sternberg et al., Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med. 31 juill, vol.371, issue.5, pp.424-457, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02169779

, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 | Annals of Oncology | Oxford Academic, 2017.

Y. Loriot, J. Eymard, A. Patrikidou, E. Ileana, C. Massard et al., Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer, Eur J Cancer. sept, vol.51, issue.14, pp.1946-52, 2015.

R. J. Van-soest, A. Nieuweboer, E. S. De-morrée, D. Chitu, A. M. Bergman et al., The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer, Eur J Cancer Oxf Engl, vol.51, issue.17, pp.2562-2571, 1990.

K. Komura, S. H. Jeong, K. Hinohara, F. Qu, X. Wang et al., Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression, Proc Natl Acad Sci. 31 mai, vol.113, issue.22, pp.6259-64, 2016.

A. Heidenreich, S. Bracarda, M. Mason, H. Ozen, L. Sengelov et al., Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme, Eur J Cancer. avr, vol.50, issue.6, pp.1090-1099, 2014.

K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodriguez-antolin et al., Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med. 27 juill, vol.377, issue.4, pp.352-60, 2017.

N. D. James, M. R. Spears, N. W. Clarke, D. P. Dearnaley, D. Bono et al., Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019), Eur Urol. juin, vol.67, issue.6, pp.1028-1066, 2015.

P. Lavaud, G. Gravis, S. Foulon, F. Joly, S. Oudard et al., Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial, Eur Urol, 2017.

D. Sur,

O. Reig, M. Marin-aguilera, G. Carrera, N. Jimenez, L. Pare et al., TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer, Eur Urol, vol.70, issue.5, pp.709-722, 2016.

G. Attard, J. F. Swennenhuis, D. Olmos, A. Reid, E. Vickers et al., Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer, Cancer Res, 2009.

, Contexte: La séquence optimale des traitements dans le cancer de la prostate métastatique résistant à la castration (CPRCm) est inconnue

, Le critère d'évaluation principal était la réponse biologique du PSA (diminution ? 50% par rapport à la valeur initiale) pour chaque traitement. Les critères secondaires étaient le meilleur bénéfice clinique, le délai jusqu'à progression du PSA, la survie globale (SG) et la toxicité. Résultats: 158 patients ont reçu DOC®CABA®iARA (groupe 1), 456 ont reçu DOC®iARA®CABA (groupe 2) et 55 ont reçu iARA®DOC®CABA (groupe 3), Évaluer le devenir des patients atteints de CPRCm traités par Docetaxel (DOC), Cabazitaxel (CABA) et un nouvel agent ciblant les récepteurs des androgènes (iARA) (acétate d'Abiratérone ou Enzalutamide), selon 3 séquences différentes. Patients et méthodes : Les données de 669 patients consécutifs atteints de CPRCm ont été recueillies rétrospectivement entre novembre 2012 et octobre, vol.8, p.0, 2016.

, Primary endpoint was prostate-specific antigen (PSA) response (decrease ?50% from baseline) with each therapy. Secondary endpoints included best clinical benefit, time to PSA progression, radiological progression-free survival (rPFS), overall survival (OS) and toxicity. Results : 158 patients received DOC®CABA®iARA (Group 1), 456 received DOC®iARA®CABA (Group 2), and 55 received iARA®DOC®CABA (Group 3). At baseline, PSA progression only and Gleason <8 were more common in Group 3. PSA response on DOC was lower in Group 3 than in other groups (p=0.02) and PSA response on CABA was higher in second than in third line (p=0.001), Mots clés : Abiraterone, inhibiteurs de l'axe du récepteur des androgènes, Cancer de la prostate résistant à la castration, Cabazitaxel, Docetaxel, Enzalutamide, Séquence Sequencing of taxanes and new androgen-targeted therapies in metastatic castrationresistant prostate cancer -Results of the international multicenter retrospective CATS database Background, 2012.